Daniela Koller1, Tammy Hua2, Julie P W Bynum3. 1. Department of Health Services Management, Munich School of Management, Ludwig Maximilian University of Munich, Munich, Germany. 2. Dartmouth College, Hanover, New Hampshire. 3. Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire.
Abstract
OBJECTIVES: To evaluate frequency of use of two anti-dementia drug classes approved for treatment of symptoms, whether populations most likely to benefit are treated, and correlates of treatment initiation. DESIGN: Nationally representative cohort study. SETTING: Fee-for-service Medicare. PARTICIPANTS: Elderly adults with dementia enrolled in Medicare Parts A, B, and D in 2009 (N = 433,559) and a subset with incident dementia (n = 185,449). MEASUREMENTS: Main outcome was any prescription fill for antidementia drugs (cholinesterase inhibitors (ChEIs) or memantine) within 1 year. RESULTS: Treatment with antidementia drugs occurred in 55.8% of all participants with dementia and 49.3% of those with incident dementia. There was no difference between ChEIs and memantine use according to dementia severity (measured as death within first year or living in residential care vs in a community setting) even though memantine is not indicated in mild disease. In incident cases, initiation of treatment was lower in residential care (relative risk (RR) = 0.82, 95% confidence interval (CI) = 0.81-0.83) and with more comorbidities (RR = 0.96, 95% CI = 0.96-0.96). Sixty percent of participants were managed in primary care alone. Seeing a neurologist (RR = 1.07, 95% CI = 1.06-1.09) or psychiatrist (RR = 1.17, 95% CI = 1.16-1.19) was associated with higher likelihood of treatment than seeing a primary care provider alone, and seeing geriatrician was associated with with lower likelihood (RR = 0.96, 95% CI = 0.93-0.99). Across the United States, the proportion of newly diagnosed individuals started on antidementia treatment varied from 32% to 66% across hospital referral regions. CONCLUSION: Antidementia drugs are used less often in people with late disease, but there is no differentiation in medication choice. Although primary care providers most often prescribe antidementia medication without specialty support, differences in practice between specialties are evident.
OBJECTIVES: To evaluate frequency of use of two anti-dementia drug classes approved for treatment of symptoms, whether populations most likely to benefit are treated, and correlates of treatment initiation. DESIGN: Nationally representative cohort study. SETTING: Fee-for-service Medicare. PARTICIPANTS: Elderly adults with dementia enrolled in Medicare Parts A, B, and D in 2009 (N = 433,559) and a subset with incident dementia (n = 185,449). MEASUREMENTS: Main outcome was any prescription fill for antidementia drugs (cholinesterase inhibitors (ChEIs) or memantine) within 1 year. RESULTS: Treatment with antidementia drugs occurred in 55.8% of all participants with dementia and 49.3% of those with incident dementia. There was no difference between ChEIs and memantine use according to dementia severity (measured as death within first year or living in residential care vs in a community setting) even though memantine is not indicated in mild disease. In incident cases, initiation of treatment was lower in residential care (relative risk (RR) = 0.82, 95% confidence interval (CI) = 0.81-0.83) and with more comorbidities (RR = 0.96, 95% CI = 0.96-0.96). Sixty percent of participants were managed in primary care alone. Seeing a neurologist (RR = 1.07, 95% CI = 1.06-1.09) or psychiatrist (RR = 1.17, 95% CI = 1.16-1.19) was associated with higher likelihood of treatment than seeing a primary care provider alone, and seeing geriatrician was associated with with lower likelihood (RR = 0.96, 95% CI = 0.93-0.99). Across the United States, the proportion of newly diagnosed individuals started on antidementia treatment varied from 32% to 66% across hospital referral regions. CONCLUSION: Antidementia drugs are used less often in people with late disease, but there is no differentiation in medication choice. Although primary care providers most often prescribe antidementia medication without specialty support, differences in practice between specialties are evident.
Authors: J Hort; J T O'Brien; G Gainotti; T Pirttila; B O Popescu; I Rektorova; S Sorbi; P Scheltens Journal: Eur J Neurol Date: 2010-10 Impact factor: 6.089
Authors: Ilene H Zuckerman; Priscilla T Ryder; Linda Simoni-Wastila; Thomas Shaffer; Masayo Sato; Lirong Zhao; Bruce Stuart Journal: J Gerontol B Psychol Sci Soc Sci Date: 2008-09 Impact factor: 4.077
Authors: Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon Journal: Ann Intern Med Date: 2007-06-05 Impact factor: 25.391
Authors: Jee-Young Han; Lilah M Besser; Chengjie Xiong; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2019 Apr-Jun Impact factor: 2.703
Authors: Laura C Maclagan; Susan E Bronskill; Michael A Campitelli; Shenzhen Yao; Christoffer Dharma; David B Hogan; Nathan Herrmann; Joseph E Amuah; Colleen J Maxwell Journal: Can J Psychiatry Date: 2020-04-10 Impact factor: 4.356
Authors: Laia Calvó-Perxas; Oriol Turró-Garriga; Joan Vilalta-Franch; Manuela Lozano-Gallego; Rosa de Eugenio; Fabián Márquez; Olga Carmona; Jordi Gich; Anna Manzano; Marta Viñas; Anna Mª Roig; Josep Garre-Olmo Journal: Drugs Aging Date: 2017-04 Impact factor: 3.923
Authors: Lynn Zhu; Paula A Rochon; Andrea Gruneir; Wei Wu; Vasily Giannakeas; Peter C Austin; Nathan M Stall; Lisa McCarthy; Amanda Alberga; Nathan Herrmann; Sudeep S Gill; Susan E Bronskill Journal: Drugs Aging Date: 2019-09 Impact factor: 3.923
Authors: Abayomi N Ogunwale; Cathleen S Colon-Emeric; Richard Sloane; Robert A Adler; Kenneth W Lyles; Richard H Lee Journal: J Bone Miner Res Date: 2019-12-12 Impact factor: 6.741
Authors: Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Jeanette Ellis; Liza Behrens; Karen Eshraghi; Shijun Zhu Journal: Clin Nurs Res Date: 2019-04-03 Impact factor: 2.075